title: Antitumor necrosis factor (TNF-a) antibodies in the treatment of renal cell cancer.
abstract: The kinase inhibitors sorafinib and sunitinib have demonstrated significant activity in renal cell carcinoma (RCC), and are now approved by the FDA for use in advanced disease. There still remains a need for novel therapies. Our group were the first to demonstrate activity of thalidomide in RCC, believed to be in part related to the modulation of tumor necrosis factor (TNF-a), a cytokine secreted by RCC with a number of tumor promoting properties. We subsequently conducted a phase II trial of the TNF-a monoclonal antibody infliximab in patients with previously treated advanced RCC. The drug was well tolerated. The response rate was 16% and stability was achieved in a further 16% of patients. Anti-TNF-a therapy may represent an important approach in the treatment of this disease.
authors.affiliation: Department of Academic Oncology, Guys Hospital, London, United Kingdom. nick.maisey@gstt.nhs.uk
authors.forename: Nick
authors.initials: N
authors.lastname: Maisey
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D000069285:Infliximab; D007680:Kidney Neoplasms / Q000188:drug therapy*; D013792:Thalidomide / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D014409:Tumor Necrosis Factor-alpha; D013792:Thalidomide; D000069285:Infliximab